4 hours ago
1
Sundry Photography/iStock Editorial via Getty Images
Update: Adds deal confirmation
Merck (NYSE:MRK) has confirmed a deal worth around $10 billion to acquire Verona Pharma (NASDAQ:VRNA), a biotech firm specializing in respiratory diseases.
The deal would value Verona at $107 per American depositary share. That represents a 23% premium to
English (US) ·